α1-adrenoceptors involvement in painful diabetic neuropathy: A role in allodynia

NeuroReport

Volumn 11, Issue 7, 2000, Pages 1417-1420

  Lee, Young Ho ^a   Ryu, Taeg Geun ^a   Park, Sang Joon ^a   Yang, Eun Jin ^a   Jeon, Byeong Hwa ^a   Hur, Gang Min ^a   Kim, Kwang Jin ^a  

^a Chungnam National University   (South Korea)

Author keywords

Allodynia; Diabetic neuropathy; Dorsal root ganglia; Spinal cord; Streptozotocin; 1 Adrenoceptors

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; PHENYLEPHRINE; PRAZOSIN; STREPTOZOCIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DIAGNOSTIC AGENT; MESSENGER RNA; TRITIUM;

ALLODYNIA; ANIMAL MODEL; ARTICLE; BINDING SITE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEUROPATHY; GENE EXPRESSION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; SPINAL CORD; SPINAL GANGLION; ANIMAL; CHEMISTRY; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; GENETICS; METABOLISM; PAIN; PAIN THRESHOLD; PATHOPHYSIOLOGY; PHYSIOLOGY; RADIOASSAY; SPRAGUE DAWLEY RAT;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; GANGLIA, SPINAL; GENE EXPRESSION; MALE; PAIN; PAIN THRESHOLD; PRAZOSIN; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA-1; RNA, MESSENGER; SPINAL CORD; TRITIUM;

EID: 0034656417     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-200005150-00013     Document Type: Article

References (24)

1. 1. Benbow SJ, Chan AW, Bowsher D et al. Diabetes Med 11, 17-21 (1994).
2. 2. Courteix C, Eschanlier A and Lavarenne J. Pain 53, 81-88 (1993).
3. 3. Malmberg AB, Yaksh TL and Calcutt NA. Neurosci Lett 161, 45-48 (1993).
4. 4. Ahlgren SC and Levine JD. Brain Res 616, 171-175 (1993).
5. 5. Ohsawa M and Kamei J. Eur J Pharmacol 372, 221-228 (1999).
6. 6. Calcutt NA and Chaplan SR. Br J Pharmacol 122, 1478-1482 (1997).
7. 7. Zhong H and Minneman KP. Eur J Pharmacol 375, 261-276 (1999).
8. 8. Schmidt RE, Plurad SB, Olack BJ and Scharp DW. Brain Res 497, 393-398 (1989).
9. 9. Cotter MA and Cameron NE. Eur J Pharmacol 343, 217-223 (1998).
10. 10. Weber LP and Macleod KM. J Pharmacol Exp Ther 283, 1469-1478 (1997).
11. 11. Angel I, Burcelin R, Proutea M et al. Endocrinology 137, 2022-2027 (1996).
12. 12. Tanaka Y, Kashiwagi A, Saeki Y et al. Eup J Pharmacol 244, 105-109 (1993).
13. 13. Kihara M and Low PA. J Physiol 422, 145-152 (1990).
14. 14. Cotter MA and Cameron NE. Eur J Pharmacol 343, 217-223 (1998).
15. 15. Biessels GJ, Cristino NA, Rutten GJ et al. Brain 122, 757-768 (1999).
16. 16. Pieribone VA, Nicholas AP, Dagerlind A and Hokfelt T. J Neurosci 14, 4252-4268 (1994).
17. 17. Kim SH and Chung JM. Pain 50, 355-363 (1992).
18. 18. Tamura E and Parry GJ. J Neurol Sci 127, 29-35 (1994).
19. 19. Yaksh TL, Pogrel JW, Lee YW and Chaplan SR. J Pharmacol Exp Ther 272, 207-214 (1995).
20. 20. Tracy DJ, Cunningham JE and Romm MA. Pain 60, 317-327 (1995).
21. 21. Ringkamp M, Grethel EJ, Choi Y et al. Pain 79, 135-141 (1999).
22. 22. Ahlgren SC, White DM and Levine JD. J Neurophysiol 68, 2077-2085 (1992).
23. 23. Ahlgren SC and Levine JD. J Neurophysiol 72, 684-92 (1994).
24. 24. Lin RZ, Chen J, Hu ZW and Hoffman BB. J Biol Chem 273, 30033-30038 (1998).